They demonstrated that the combination of an Apt (GD2 Apt) and i‐motif represents a dependable strategy for cancer therapy, particularly when the target is also found on healthy cells, suggesting considerable clinical promise for various cancer treatments. Here, LYPLA2P1 is linked to cancer.